The role of poly adenosine diphosphate–ribose polymerase (PARP) inhibitors in advanced BC is well established for the treatment of germline BRCA1/2 mutated (gBRCA1/2m) HER2-negative BC, regardless of hormone receptor (HR) expression. Here, BRCA1 is linked to breast cancer.